Keros Therapeutics (KROS) Competitors

Keros Therapeutics (NASDAQ:KROS) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Is KROS or IBRX more profitable?

ImmunityBio has a net margin of -8,016.83% compared to Keros Therapeutics' net margin of -27,890.94%. ImmunityBio's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-27,890.94%	-41.74%	-38.42%
ImmunityBio	-8,016.83%	N/A	-110.02%

Do insiders & institutionals believe in KROS or IBRX?

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Comparatively, 83.4% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, KROS or IBRX?

Keros Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Which has better earnings & valuation, KROS or IBRX?

Keros Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$3.55M	167.59	-$152.99M	-$5.01	-2.92
ImmunityBio	$14.75M	147.02	-$583.20M	-$0.63	-4.03

Do analysts recommend KROS or IBRX?

Keros Therapeutics presently has a consensus target price of $40.33, indicating a potential upside of 175.31%. ImmunityBio has a consensus target price of $12.19, indicating a potential upside of 379.82%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer KROS or IBRX?

Keros Therapeutics received 44 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 69.89% of users gave Keros Therapeutics an outperform vote while only 50.00% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
Keros Therapeutics	Outperform Votes 65 69.89%	Underperform Votes 28 30.11%
ImmunityBio	Outperform Votes 21 50.00%	Underperform Votes 21 50.00%

Does the media favor KROS or IBRX?

In the previous week, Keros Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 7 mentions for Keros Therapeutics and 5 mentions for ImmunityBio. Keros Therapeutics' average media sentiment score of 1.55 beat ImmunityBio's score of 0.61 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmunityBio	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Keros Therapeutics beats ImmunityBio on 10 of the 19 factors compared between the two stocks.